Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes - Jojima, T; Tomotsune, T; Iijima, T (Diabetol Metab Syndr, 2016)